Browsing Tag
NSE
200 posts
SIS Limited (NSE: SIS) buys minority stake in Updater Services as business services sector consolidation stays in focus
SIS Limited bought 4.20 percent of Updater Services for ₹51.39 crore. Find out what this means for #SIS and India’s services sector.
June 7, 2026
Repro India stock watch: What the STT Global Data Centres land deal means for investors
Find out how STT Global Data Centres’ Navi Mumbai land deal with Repro India could reshape India’s data centre infrastructure race.
June 7, 2026
BHEL bags Meja thermal order, but can the PSU convert its order book into margins?
Find out how BHEL’s ₹21,000 crore Meja power order could reshape its order book, stock sentiment and India’s thermal power strategy.
June 7, 2026
Ola Electric raises Rs 780cr through QIP as #OLAELEC tests battery cell localisation strategy
Ola Electric raised ₹780 crore via QIP as #OLAELEC rebounds. The real test is whether funding can fix margins and EV execution.
June 7, 2026
ACME Solar QIP puts #ACMESOLAR in focus as Rs 2,800cr raise strengthens renewable growth funding
ACME Solar raised ₹2,800 crore through QIP as #ACMESOLAR trades near highs. Find out how the fundraise changes its growth test.
June 6, 2026
IDFC First Bank got forensic clarity, but can #IDFCFIRSTB rebuild investor trust?
IDFC First Bank’s forensic audit says the fraud was isolated. Find out what #IDFCFIRSTB investors should watch next.
June 6, 2026
Lupin and Natco FDA approval puts #LUPIN in focus as oncology generic pipeline strengthens
Lupin and Natco won FDA approval for Eribulin generic. #LUPIN investors now face the real test: launch timing and U.S. pricing.
June 5, 2026
Ravindra Energy plans Rs 200cr rights issue as #RELTD shareholders face capital allocation test
Ravindra Energy’s ₹200 crore rights issue opens soon. #RELTD investors face a dilution and renewable growth test.
June 4, 2026
AstraZeneca Pharma India exits factory licence as #ASTRAZEN investors assess asset-light model
AstraZeneca Pharma India surrendered its factory licence as #ASTRAZEN exits manufacturing. Find out what the shift means for investors.
June 4, 2026
Is HFCL (NSE: HFCL) quietly building a serious defence technology business beyond telecom?
HFCL is moving Thermal Weapon Sights into its defence unit. #HFCL investors now face a bigger question: can orders become execution?
June 3, 2026